Results 131 to 140 of about 39,993 (263)
Seeing Invisible Oligomers: Rethinking α‐Synuclein Pathology Through Proximity Ligation Assay
Abstract Parkinson's disease (PD) and multiple system atrophy are defined by α‐synuclein (αSYN)‐positive inclusions – Lewy bodies (LBs) and glial cytoplasmic inclusions – yet mounting evidence indicates that these inclusions represent only a fraction of disease‐relevant pathology.
Hiroaki Sekiya +3 more
wiley +1 more source
Heterogenous Neuropathology in a Pedigree with RAB39B‐Related Parkinson's Disease
Abstract Background In 2015, we reported a family with Parkinson's disease resulting from the RAB39B p.G192R (c.574G>A) variant. Since then, two affected brothers from the family have undergone autopsy. Objectives To characterize neuropathological findings, assess intracellular distribution of RAB39B protein, and examine the effect of p.G192R on α ...
Caitlin Latimer +15 more
wiley +1 more source
Synaptic phosphorylated a-synuclein in dementia with Lewy bodies [PDF]
Dementia with Lewy bodies is characterized by the accumulation of Lewy bodies and Lewy neurites in the CNS, both of which are composed mainly of aggregated a-synuclein phosphorylated at Ser129.
Andilla, Jordi +22 more
core +1 more source
Abstract Background Although clinical markers (eg, motor and cognitive impairment) in isolated rapid eye movement sleep behavior disorder (iRBD) are associated with faster phenoconversion, their longitudinal trajectory patterns (linear or nonlinear) remain unclear.
Li Zhou +17 more
wiley +1 more source
Abstract Background Despite widespread cortical involvement in Lewy body diseases, conventional gray matter magnetic resonance imaging (MRI) shows limited sensitivity. Diffusion‐weighted MRI‐derived microstructural measures have shown utility in Alzheimer's disease, but their application across the Lewy body disease spectrum remains limited ...
Angeliki Zarkali +9 more
wiley +1 more source
The GBA1 p.E427K (p.E388K) Variant Is a Risk Factor for Synucleinopathies: A Meta‐Analysis
Abstract Background Variants in GBA1 are important genetic risk factors for synucleinopathies, including Parkinson's disease (PD). Although several GBA1 variants are established risk or severity modifiers, the role of the p.E427K variant remains unclear.
Leah V. Chifamba +30 more
wiley +1 more source
Dementia with lewy bodies: A clinical overview
\ua9 2017 by Taylor & Francis Group, LLC. Dementia with Lewy bodies (DLB) is now the preferred term (McKeith et al., 1996) for a variety of clinical diagnoses including diuse Lewy body disease (DLBD) (Kosaka et al., 1984; Dickson et al., 1987; Lennox
McKeith IG
core
Cognitive deficits and structural brain changes associated with dementia and visual hallucinations in Parkinson's disease [PDF]
[eng] Cognitive impairment of different degrees and hallucinations are common complications of chronic Parkinson's disease (PD). The pathogenesis, pathophysiology, and relationship between cognitive deficits and presence of hallucinations are not fully ...
Ramírez Ruiz, Blanca
core
Aim: To investigate quality of life (QOL) and the effect of memantine treatment in patients with Lewy body dementias. Methods: A secondary analysis of a randomized controlled study in 70 patients with Parkinson's disease dementia (PDD) or dementia with ...
Aarsland, Dag +6 more
core +1 more source
Abstract Background Lysosomal dysfunction is central to Parkinson's disease (PD) pathogenesis, with GBA1 representing the strongest established genetic risk factor. Numerous other genes involved in lysosomal sphingolipid, glycosphingolipid, and ceramide metabolism have been proposed as contributors to PD, highlighting the need for genetic analyses ...
Konstantin Senkevich +21 more
wiley +1 more source

